Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Benza (Pittsburgh, United States of America). Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. 1986

Member's Comments

No comment yet.

Related content which might interest you: End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension Source: Eur Respir Rev 2013; 22: 495-502 Year: 2013 Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001 Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry Source: ERJ Open Res, 7 (2) 00046-2021; 10.1183/23120541.00046-2021 Year: 2021 Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study Source: Eur Respir J, 50 (1) 1700217; 10.1183/13993003.00217-2017 Year: 2017 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights Source: Eur Respir J 2015; 46: 414-421 Year: 2015 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry Source: Eur Respir J, 55 (5) 1901747; 10.1183/13993003.01747-2019 Year: 2020 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort Source: Eur Respir J, 57 (6) 2002591; 10.1183/13993003.02591-2020 Year: 2021 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020